Downstream Processing Featured Articles

31. FDA Reports Conditions Observed At New England Compounding Center Facility 10/26/2012

    Recently, the U.S. Food and Drug Administration released a copy of the FDA Form 483 issued to the New England Compounding Center (NECC). The FDA observed and has since confirmed contaminated products and listed a number of observations regarding conditions in the clean room at NECC’s Framingham, Mass. facility.

32. Major Cancer Protein Amplifies Global Gene Expression, NIH Study Finds 9/27/2012

    Scientists may have discovered why a protein called MYC can provoke a variety of cancers. Like many proteins associated with cancer, MYC helps regulate cell growth.

33. 3M Purification Inc. Introduces LifeASSURE PDA Gamma Compatible And Sterile Capsule Filters 5/4/2012

    3M Purification Inc. has expanded its portfolio of the LifeASSURE PDA Series of sterilizing grade polyethersulfone (PES) membrane filters. 

34. Repligen Acquires Bioprocessing Business Of Refine Technology 6/3/2014

    Repligen Corporation announced recently that it has acquired the business of Refine Technology (“Refine”), including Refine’s Alternating Tangential Flow (“ATF”) System, a market-leading device used to significantly increase product yield during the fermentation step of the biologic drug manufacturing process.

35. The Process Behind The Potential: Therapy For HPV16-Related Malignancies 2/18/2020

    HPV-related malignancies are poised to skyrocket over the next thirty+ years. Here's a look into Cue Biopharma’s engineering-centric approach to in vivo tumor antigen specific T cell activation to treat these cancers.

36. Immunovative, Inc. Announces Expanded Collaboration With The University Of Arizona To Investigate AlloStim™ And AlloVax™ In Leukemias And Cancers That Affect Children 11/13/2012

    Immunovative, Inc. ("IMUN" or the "Company") (OTCQB: IMUN) has today announced that Immunovative Therapies, Ltd. ("ITL") and The University of Arizona Cancer Center (UACC) and The University of Arizona Medical Center (UAMC) (University Campus and Diamond Children's) have agreed to expand their current collaboration to include investigator-initiated clinical trials using AlloStim™ and AlloVax™, with an initial focus on adult and pediatric leukemias and childhood cancers that are refractory to standard treatments.

37. Researchers Identify Role For Protein Linked To Obesity, Type 2 Diabetes 12/17/2012

    Researchers at UT Southwestern Medical Center have taken another step toward better understanding the metabolic functions of obesity and its connection to type 2 diabetes.

38. First Patient Treated In Genelux Phase I Trial With GL-ONC1 At Memorial Sloan Kettering Cancer Center 2/6/2013

    Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based cancer therapies and companion diagnostics, today announced that researchers at Memorial Sloan Kettering Cancer Center (MSKCC) in New York treated the first patient in a Phase I clinical trial of GL-ONC1 in people with malignant pleural effusion, a complication that occurs in about 30 percent of lung cancers.

39. Theratechnologies Secures US Patent For Its Novel Peptide TH1173 1/29/2013

    Theratechnologies Inc. (TSX:TH)(NASDAQ:THER) today reported that the US Patent and Trademark Office (USPTO) has granted a patent (US Patent No. 8,361,964) for its second generation growth-hormone releasing factor (GRF) peptide, TH1173, providing for patent protection beyond 2030.

40. Rare Cancers Yield Potential Source Of Tumor Growth 9/17/2012

    Researchers at the National Institutes of Health have discovered a genetic mutation that appears to increase production of red blood cells in tumors.